KalVista Pharma - Public Comps and Valuation Multiples

KalVista Pharma Overview

About KalVista Pharma

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

Founded

2004

HQ

Employees

150

Website

kalvista.com

Sectors

Drug Development & Therapeutics
Small Molecules
BioTech
DeepTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$347M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

KalVista Pharma Financials

KalVista Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, KalVista Pharma achieved revenue of n/a and an EBITDA of -$131M.

KalVista Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See KalVista Pharma valuation multiples based on analyst estimates

KalVista Pharma P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	n/a	n/a	XXX	XXX	XXX
Gross Profit	n/a	n/a	XXX	XXX	XXX
Gross Margin	NaN%	NaN%	XXX	XXX	XXX
EBITDA	-$110M	-$131M	XXX	XXX	XXX
EBITDA Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Profit	-$82.3M	-$92.9M	XXX	XXX	XXX
Net Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

KalVista Pharma Stock Performance

As of April 15, 2025, KalVista Pharma's stock price is $12.

KalVista Pharma has current market cap of $594M, and EV of $347M.

See KalVista Pharma trading valuation data

KalVista Pharma Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$347M	$594M	XXX	XXX	XXX	XXX	$-3.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

KalVista Pharma Valuation Multiples

As of April 15, 2025, KalVista Pharma has market cap of $594M and EV of $347M.

KalVista Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate KalVista Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for KalVista Pharma and 10K+ public comps

KalVista Pharma Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$347M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	-2.1x	XXX	XXX	XXX
P/E	-3.8x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get KalVista Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

KalVista Pharma Valuation Multiples

KalVista Pharma's NTM/LTM revenue growth is Infinity%

KalVista Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.

Over next 12 months, KalVista Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate KalVista Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for KalVista Pharma and other 10K+ public comps

KalVista Pharma Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	19%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	$0.9M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	n/a	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry